NUOPTY
DEAD

Serial Number

87650646

Owner

H. Lundbeck A/S

Attorney

Claudia A. Smith

Filing Date

Oct 18, 2017

Add to watchlist:

No watchlists yet
View on USPTO

NUOPTY Trademark

Serial Number: 87650646

NUOPTY is a trademark filed by H. Lundbeck A/S on October 18, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

October 18, 2017

Registration Date

Not Registered

Published for Opposition

May 15, 2018

Goods & Services

Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy; pharmaceutical preparations and substances for the prevention and treatment of Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; diagnostic agents, reagents, preparations and substances for medical purposes

Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for pharmaceuticals, syringes and needles for injections and medical purposes; integrated medical systems, namely, medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems

Filing History

ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Jul 2, 2021 MAB5
ABANDONMENT - AFTER PUBLICATION
Jul 2, 2021 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Jul 1, 2021 EXAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2020 EXRA
SOU EXTENSION 5 GRANTED
Dec 9, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 23, 2020 AITU
SOU EXTENSION 5 FILED
Nov 12, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 12, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 8, 2020 EXRA
SOU EXTENSION 4 GRANTED
Jul 6, 2020 EX4G
SOU EXTENSION 4 FILED
Jul 6, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 6, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 6, 2019 EXRA
SOU EXTENSION 3 GRANTED
Dec 4, 2019 EX3G
SOU EXTENSION 3 FILED
Dec 4, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 4, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 14, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jun 12, 2019 EX2G
SOU EXTENSION 2 FILED
Jun 12, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 12, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2018 EXRA
SOU EXTENSION 1 GRANTED
Dec 19, 2018 EX1G
SOU EXTENSION 1 FILED
Dec 19, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 19, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 10, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 15, 2018 NPUB
PUBLISHED FOR OPPOSITION
May 15, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 25, 2018 NONP
ASSIGNED TO LIE
Apr 9, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 2, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 28, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 28, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 28, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 28, 2018 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Feb 1, 2018 GPRN
PRIORITY ACTION E-MAILED
Feb 1, 2018 GPRA
PRIORITY ACTION WRITTEN
Feb 1, 2018 CPRA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 31, 2018 PARI
ASSIGNED TO EXAMINER
Jan 26, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 27, 2017 NWOS
NEW APPLICATION ENTERED
Oct 21, 2017 NWAP